Please assess the completion status of the following clinical trial:

Trial Title: Early Airway Response to Allergen in Asthmatics (MK-0000-176)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of mild to moderate Asthma~* In good general health (except for asthma)~* Stable and free of respiratory infection~* Nonsmoker~* Females highly unlikely to conceive (surgically sterilized, postmenopausal, or agrees to use 2 acceptable methods of birth control)~Exclusion Criteria:~* Nursing mother~* Recent or ongoing upper or lower respiratory tract infection~* Unable to refrain from or anticipates the use of any prescription and non-prescription drugs~* Consumes excessive amounts of alcohol or caffeine~* History of stroke, chronic seizures, or major neurological disorder~* History of cancer~* Received a vaccination within the past 3 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Placebo
- Montelukast (Type: EXPERIMENTAL): Montelukast
- Nedocromil (Type: EXPERIMENTAL): Nedocromil
- Mometasone (Type: EXPERIMENTAL): Mometasone

Based on this trial design, predict the completion outcome and termination type (if applicable).